H. Lundbeck A/S

🇩🇰Denmark

Country: 🇩🇰Denmark

Ownership: Public, Subsidiary

Established: 2000-01-01

Employees: 5.6K

Market Cap: -

Website: http://www.lundbeck.com

Clinical Trials

Open-label Safety Extension Study of 15 and 20 mg of Vortioxetine (Lu AA21004) in Long-term Treatment of Major Depressive Disorder in Adults

Phase 3

Completed

Conditions: Major Depressive Disorder

Interventions: Drug: Vortioxetine (Lu AA21004)

First Posted Date: 2011-03-25

Last Posted Date: 2014-02-11

Lead Sponsor: H. Lundbeck A/S

Target Recruit Count: 71

Registration Number: NCT01323478

Safety and Efficacy of Zicronapine in Patients With Schizophrenia

Phase 3

Completed

Conditions: Schizophrenia

Interventions: Drug: Zicronapine
Drug: Risperidone

First Posted Date: 2011-02-14

Last Posted Date: 2016-11-08

Lead Sponsor: H. Lundbeck A/S

Target Recruit Count: 160

Registration Number: NCT01295372

Locations: 🇫🇷
FR004, Strasbourg, France
🇨🇿
CZ001, Brno, Czech Republic
🇫🇷
FR003, Toulon, France

and more 21 locations

Study of Azilect® (Rasagiline) in Levodopa-treated Parkinson's Disease Patients With Motor Fluctuations in Korea

Phase 3

Completed

Conditions: Parkinson's Disease

Interventions: Drug: Placebo
Drug: Azilect®

First Posted Date: 2010-12-31

Last Posted Date: 2013-12-03

Lead Sponsor: H. Lundbeck A/S

Target Recruit Count: 132

Registration Number: NCT01268891

Efficacy and Tolerability of Escitalopram and Duloxetine in Outpatients With Major Depressive Disorder

Phase 4

Completed

Conditions: Major Depressive Disorder

Interventions: Drug: Duloxetine
Drug: Escitalopram

First Posted Date: 2010-06-22

Last Posted Date: 2016-11-08

Lead Sponsor: H. Lundbeck A/S

Target Recruit Count: 294

Registration Number: NCT01148472

Randomised Placebo-controlled Duloxetine-referenced Study of Efficacy and Safety of 15 and 20 mg of Vortioxetine (Lu AA21004) in Acute Treatment of Major Depressive Disorder in Adults

Phase 3

Completed

Conditions: Major Depressive Disorder

Interventions: Drug: Placebo
Drug: Vortioxetine (Lu AA21004)
Drug: Duloxetine

First Posted Date: 2010-06-10

Last Posted Date: 2014-02-11

Lead Sponsor: H. Lundbeck A/S

Target Recruit Count: 607

Registration Number: NCT01140906

Lu AE58054 Added to Donepezil for the Treatment for Moderate Alzheimer's Disease

Phase 2

Completed

Conditions: Alzheimer's Disease

Interventions: Drug: Lu AE58054
Drug: Placebo

First Posted Date: 2009-11-25

Last Posted Date: 2012-01-06

Lead Sponsor: H. Lundbeck A/S

Target Recruit Count: 278

Registration Number: NCT01019421

Locations: 🇨🇿
CZ001, Kladno, Czech Republic
🇨🇿
CZ005, Praha, Czech Republic
🇨🇿
CZ006, Praha, Czech Republic

and more 48 locations

Safety Study of Carbamylated Erythropoietin to Treat Patients With the Neurodegenerative Disorder Friedreich's Ataxia

Phase 2

Completed

Conditions: Friedreich's Ataxia

Interventions: Drug: Placebo
Drug: Lu AA24493

First Posted Date: 2009-11-19

Last Posted Date: 2016-11-08

Lead Sponsor: H. Lundbeck A/S

Target Recruit Count: 36

Registration Number: NCT01016366

Locations: 🇦🇹
AT001, Innsbruck, Austria
🇩🇪
DE001, Munich, Germany
🇩🇪
DE004, Bochum, Germany

and more 4 locations

Escitalopram in Patients With Social Anxiety Disorder

Phase 4

Completed

Conditions: Social Anxiety Disorder

Interventions: Drug: Escitalopram

First Posted Date: 2009-05-15

Last Posted Date: 2011-06-10

Lead Sponsor: H. Lundbeck A/S

Target Recruit Count: 30

Registration Number: NCT00902226

Locations: 🇷🇺
RU001, Moscow, Russian Federation

Escitalopram in Patients With Generalized Anxiety Disorder

Phase 4

Completed

Conditions: Generalized Anxiety Disorder

Interventions: Drug: Escitalopram

First Posted Date: 2009-05-15

Last Posted Date: 2011-06-10

Lead Sponsor: H. Lundbeck A/S

Target Recruit Count: 30

Registration Number: NCT00902564

Locations: 🇷🇺
RU001, Moscow, Russian Federation

Safety and Pharmacokinetic Study of Carbamylated Erythropoietin (CEPO) to Treat Patients With Acute Ischemic Stroke

Phase 1

Completed

Conditions: Acute Ischemic Stroke

Interventions: Drug: Lu AA24493 (CEPO)
Drug: Placebo

First Posted Date: 2009-03-27

Last Posted Date: 2011-04-20

Lead Sponsor: H. Lundbeck A/S

Target Recruit Count: 24

Registration Number: NCT00870844

Locations: 🇸🇬
SG003, Singapore, Singapore
🇫🇮
FI004, Helsinki, Finland
🇳🇱
NL005, Breda, Netherlands

and more 2 locations

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy